Undisclosed ARID1B degrader / Foghorn Therap - LARVOL DELTA

Identification of first in class selective ARID1B degraders (AACR 2026) - "These compounds exhibit on mechanism activity, high selectivity, and downstream transcriptional modulation. This work establishes ARID1B degradation as a promising therapeutic strategy and provides a blueprint for targeting previously intractable chromatin remodelers."

Gastric Cancer • Oncology • Ovarian Cancer • Solid Tumor • ARID1A • ARID1B • CRBN

Title: Identification of first-in-class selective ARID1B degraders (GlobeNewswire) - "Foghorn Therapeutics presents new preclinical data...at the 2026 AACR Annual Meeting....Preclinical data of this previously intractable target show: Successful identification of the first selective ARID1B binders; Robust degradation via VHL and CRBN-based mechanisms; Clear on-mechanism activity with downstream transcriptional modulation."

Preclinical • Solid Tumor

Title: Leveraging paralog relationships for targeting chromatin modulators in cancer: ARID1B and SMARCA2 (FHD-909) (GlobeNewswire) - "Foghorn Therapeutics presents new preclinical data...at the 2026 AACR Annual Meeting....Complete regression in pre-clinical syngeneic efficacy models of FHD-909 in combination with an anti-PD1 antibody, with tumors failing to regrow after dosing halted. Tumor rejection upon rechallenge, where attempts to implant fresh tumor on the opposite flank of previously treated animals with FHD-909 plus an anti-PD1 antibody were not successful, suggesting an immune memory effect....Robust degradation achieved with cereblon-based selective ARID1B degraders with potential for oral bioavailability."

Preclinical • Solid Tumor

Program Overview and Upcoming Milestones:…Selective ARID1B degrader program (GlobeNewswire) - "The preclinical program has made meaningful progress with the development of both VHL- and cereblon-based bifunctional degraders designed with potential for oral delivery. Both have achieved selective degradation of ARID1B, confirming effective target engagement, and have demonstrated modulation of downstream target genes consistent with ARID1B pathway disruption. Advancing towards in vivo proof of concept in 2026."

Preclinical • Solid Tumor

First-in-class Selective ARID1B degrader program advancing towards in vivo proof of concept in 2026. (GlobeNewswire)

Preclinical • Solid Tumor

Foghorn is developing a Selective ARID1B degrader that is advancing towards in vivo proof of concept in 2026. Key program updates include: (Foghorn Press Release) - "Developed VHL and cereblon based bifunctional degraders with potential for oral delivery; Selective degradation of ARID1B achieved; Modulation of downstream target genes following ARID1B degradation"

Preclinical • Solid Tumor

Program Overview and Upcoming Milestones (GlobeNewswire) - "Continued progress on Selective EP300 degrader and Selective ARID1B degrader, with program updates expected in Q4 2025...Selective CBP degrader program....On track for IND-enabling studies, targeting an IND in 2026."

IND • Preclinical • Diffuse Large B Cell Lymphoma • Estrogen Receptor Positive Breast Cancer • Hematological Malignancies • Multiple Myeloma • Solid Tumor

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update (GlobeNewswire) - "Selective CBP degrader on track for IND-enabling studies, targeting IND in 2026; Continued progress on Selective EP300 degrader and Selective ARID1B degrader with program updates expected in H2 2025."

IND • Preclinical • Oncology

Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025 (GlobeNewswire) - "Selective ARID1B degrader program: Developed highly potent and selective binders. Preclinical data demonstrated potent and selective small molecule binders to ARID1B; Selective degradation of ARID1B achieved. Foghorn has successfully selectively degraded ARID1B and expects to provide an update on the Selective ARID1B degrader program in 2025."

Preclinical • Bladder Cancer • Colorectal Cancer • Endometrial Cancer • Ovarian Cancer • Urothelial Cancer